Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of Acalabrutinib with Fluconazole or Isavuconazole in Healthy Subjects
NCT05140096Phase 1Completed
- Sponsor
- Acerta Pharma
- Start
- Jan 2020
- Primary completion
- Apr 2020
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of acalabrutinib tablet (Variant 1) in chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL) and small lymphocytic lymphoma (SLL) (2 arms), sponsored by Acerta Pharma. Primary endpoints: Area Under the Plasma Concentration-time Curve to the Last Observed Nonzero Concentration, Area Under the Plasma Concentration-time Curve to Infinity and 1 more. Started Jan 2020; status: completed.
02
Drugs
acalabrutinib tablet (Variant 1)
03
Conditions
chronic lymphocytic leukemia (CLL)mantle cell lymphoma (MCL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT05140096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05140096.